Abstract 7932: Efficacy of Finerenone in Primary Cardiovascular Prevention: A Mechanistic Analysis Using the AHA PREVENT™ Risk Score
Background: The prespecified FIDELITY analysis of two phase 3 trials found that finerenone reduced the risk of cardiovascular (CV) events in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD); however, the magnitude of benefit in patients without prior CV disease (CVD) has not been characterized. T...